How Does Wegovy Help with Weight Loss?
Wegovy (semaglutide) is FDA-approved for chronic weight management in adults with obesity or overweight plus at least one weight-related condition, like hypertension or type 2 diabetes. In clinical trials, patients taking the highest dose (2.4 mg weekly) lost an average of 15-17% of body weight over 68 weeks, compared to 2-3% with placebo. This comes from reduced appetite, slower gastric emptying, and better blood sugar control via GLP-1 receptor agonism.[1][2]
Does Wegovy Improve Heart Health?
Yes, Wegovy reduces major cardiovascular events by 20% in adults with established heart disease and obesity or overweight. The SELECT trial showed lower risks of heart attack, stroke, and cardiovascular death, marking it as the first weight-loss drug with proven heart protection.[3][4]
What About Blood Sugar and Diabetes Prevention?
Wegovy lowers HbA1c by 1-2% and fasting blood sugar in people with or without diabetes. STEP trials noted better glycemic control, delaying or preventing type 2 diabetes onset in prediabetic patients.[1][2]
Are There Benefits Beyond Weight and Heart?
Patients report improved quality of life, including better mobility, reduced joint pain, and less sleep apnea severity. Some studies link it to lower inflammation markers and potential kidney protection in obese patients with chronic kidney disease.[4][5]
Who Gets the Most Benefits?
Greatest effects occur in those with BMI over 30 or 27+ with comorbidities, when combined with diet and exercise. Women and those with higher baseline weight often see larger losses. Long-term data (up to 2 years) shows sustained benefits with continued use.[1][3]
What Risks Offset These Benefits?
Common side effects include nausea (44%), diarrhea (30%), and vomiting (24%), mostly mild and early. Rare risks: gallbladder issues (4%), pancreatitis, or thyroid tumors (in rodents, not confirmed in humans). Not for those with medullary thyroid cancer history or multiple endocrine neoplasia syndrome type 2.[2][6]
[1]: Novo Nordisk, Wegovy Prescribing Information (FDA-approved label, 2023).
[2]: NEJM, STEP 1 Trial (Wilding et al., 2021). https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[3]: NEJM, SELECT Trial (Lincoff et al., 2023). https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
[4]: Novo Nordisk Press Release, SELECT Results (2023).
[5]: ADA Guidelines on GLP-1 Agonists (2024).
[6]: FDA Safety Communication on Semaglutide (2023).